The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It jokingly suggests the creation of a new chemical called RU99999.
Hair loss treatments, including PP405, minoxidil, finasteride, and RU58841, with hopes for future solutions. Participants discuss the emotional impact of hair loss and consider alternatives like hair transplants or acceptance.
A user who had FUT surgery for 2877 grafts with Dr Jerry Wong of Hasson & Wong that resulted in low growth and an abnormally wide scar, suggesting negligence by the doctor and possibly illegal behaviour by an unqualified technician. The post sparked discussion about seeking legal action, as well as criticism of the clinic's high cost.
The user experienced improved self-confidence and hair regrowth using finasteride, minoxidil, and dermarolling. Visible results were noted after about three months, with microneedling done once a week.
Orient Bio is developing a PLGA formulated version of Cyclosporine A to stimulate hair growth without its immunosuppressant effects. Users discuss various treatments like Clascoterone, PP405, minoxidil, and tacrolimus, expressing hope for new developments and sharing personal experiences with these treatments.
RU58841 showed promise for treating androgenic alopecia but research was halted due to financial and organizational changes. There were no significant safety concerns reported in human trials.
A new stem cell method for culturing hair follicles is being developed as an alternative to Minoxidil, finasteride, and RU58841. There are concerns about its cost and accessibility despite plans for commercialization.
The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.
SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.
The conversation discusses using RU58841, Minoxidil, and finasteride for hair loss treatment. It focuses on homebrewing RU58841 while using other treatments.
The conversation discusses the application of RU58841 for hair loss, with the user applying 1.75 mg at 5% concentration for half an hour daily. The user mentions managing seborrheic dermatitis while using this treatment.
A 25-year-old male experienced noticeable temple regrowth using 1mg finasteride, 2.5mg oral minoxidil, and 2mg GHK-Cu over three months. The user is pleased with the progress, especially on the left temple.
A user on Finasteride for over a year is asking if taking Glycine 1000 mg at night along with morning collagen peptides will increase DHT and cause hair loss. They are concerned about the potential impact on their hair loss treatment.
A user with stage 1 hair loss is inquiring about the release date of GT20029, hoping to use it instead of Minoxidil and finasteride, as they believe it has better results. They want to know if it will be available in the next couple of years.
Hair loss discussion includes Amplifica, a new treatment by Dr. Rassman and Dr. Plikus using molecules from hairy moles. No progress updates mentioned.
The conversation is about managing allopregnanolone deficiency caused by 5-alpha-reductase inhibitors like finasteride or dutasteride. Specific treatments discussed for hair loss include Minoxidil, finasteride, and RU58841.
The conversation discusses the potential of Verteporfin for hair regeneration and improving hair transplant surgery to leave no scars. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
The conversation is about the potential of SCUBE3 to regrow a juvenile hairline. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
The user received 1600 hair grafts but is dissatisfied and plans a second transplant for better coverage. They use minoxidil and finasteride and are considering adding dutasteride.
User fought hair loss with Derminator microneedling, topical and oral minoxidil, and a 2000 FUE hair transplant. Derminator was a game changer, preventing further loss.
RU58841 had mixed results for hair regrowth, with some users experiencing no change and others noting regrowth but also side effects like libido issues and chest pain. Some users combined it with other treatments like finasteride and dutasteride, with varying effectiveness.
An 18-year-old has been using minoxidil and finasteride for hair loss since age 15, recently adding dutasteride and GHK-Cu, but sees no significant improvement and is considering a hair transplant. Concerns are raised about using hormone suppressors at a young age, with suggestions to explore other treatments like dermarolling, diet changes, and checking for deficiencies.
Hair loss can be treated by correcting glucose metabolism in hair follicles and using equol as a safer DHT blocker. Production of these treatments is starting soon, and a Discord channel is available for more information.
RU58841 is being discussed as a hair loss treatment without using finasteride or dutasteride. Users are sharing their experiences and success with RU58841 alone.
The conversation discusses androgen receptor degraders for hair loss, highlighting their potential advantages over traditional AR blockers like RU58841 and pyrilutamide. Concerns about the safety and cost of these treatments are also mentioned.
The user has been using Minoxidil, finasteride, and a dermaroller for a year with little effect on hair loss. They are considering a hair transplant and are questioning the number of grafts needed and the feasibility of transplanting onto a partially bald scalp.
A 23-year-old user shares their hair regrowth journey, questioning if genetics or other factors are at play. They use Rogaine, finasteride, vitamin B12, biotin, Thera M Plus, and derma stamping, and seek advice on their regimen and hair growth patterns.